3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Neoplasms
2
Neoplasm Metastasis
2
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
fludarabine phosphate
31
Cyclophosphamide
27
Mycophenolic Acid
22
Whole-Body Irradiation
21
Tacrolimus
21
ruxolitinib
19
Peripheral Blood Stem Cell Transplantation
19
Busulfan
19
Antilymphocyte Serum
16
fludarabine
14
Melphalan
12
Methotrexate
11
Cyclosporine
10
thymoglobulin
9
Cord Blood Stem Cell Transplantation
7
Sirolimus
6
Radiotherapy
6
Etoposide
6
Azacitidine
6
Stem Cell Transplantation
5
Granulocyte Colony-Stimulating Factor
5
Cyclosporins
4
pomalidomide
3
parsaclisib
3
Surveys and Questionnaires
3
Rituximab
3
Prednisone
3
Filgrastim
3
Cytarabine
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Primary Myelofibrosis
×
navitoclax
×
Clear all
NCT04472598
2026-03-23
TRANSFORM-1
AbbVie
Phase 3
Completed
252 enrolled
17 charts